Objective: To study the significance of c-myc and c-erbB-2 oncogene expression in gastric cancer. Methods: 81 gastric cancer specimens were detected for c-myc and c-erbB-2 oncogene amplification using non-radioactive in situ hybridization method. Results: The amplification rates for c-myc and c-erbB-2 were 67.9% and 50.6% respectively, and there were significant correlation in the amplification of these two genes (χ2 = 7.26, P < 0.01). Conclusions: The amplification of c-myc and c-erbB-2 may play an important role in gastric cancer development, and these two genes may have synergistic effect.
References
[1]
Amati, B., Alevizopoulos, K. and Vlach, J. (1998) Myc and the Cell Cycle. Frontiers in Bioscience, 3, D250-268. https://doi.org/10.2741/A239
[2]
Knudsen, E.S., McClendon, A.K., Franco, J., Ertel, A., Fortina, P. and Witkiewicz, A.K. (2015) RB Loss Contributes to Aggressive Tumor Phenotypes in MYC-Driven Triple Negative Breast Cancer. Cell Cycle, 14, 109-122.
https://doi.org/10.4161/15384101.2014.967118
[3]
Tang, B., Xie, R., Qin, Y., Xiao, Y.F., Yong, X., Zheng, L., Dong, H. and Yang, S.M. (2016) Human Telomerase Reverse Transcriptase (hTERT) Promotes Gastric Cancer Invasion through Cooperating with c-Myc to Upregulate Heparanase Expression. Oncotarget, 7, 11364-11379. https://doi.org/10.18632/oncotarget.6575
[4]
Ishii, H.H., Gobé, G.C., Pan, W., Yoneyama, J. and Ebihara, Y. (2002) Apoptosis and Cell Proliferation in the Development of Gastric Carcinomas: Associations with c-myc and p53 Protein Expression. Journal of Gastroenterology and Hepatology, 17, 966-972. https://doi.org/10.1046/j.1440-1746.2002.02805.x
[5]
Br?gelmann, J., B?hm, S., Guthrie, M.R., Mollaoglu, G., Oliver, T.G. and Sos, M.L. (2017) Family Matters: How MYC Family Oncogenes Impact Small Cell Lung Cancer. Cell Cycle, 16, 1489-1498. https://doi.org/10.1080/15384101.2017.1339849
[6]
Xie, D., Sham, J.S., Zeng, W.F., Lin, H.L., Che, L.H., Wu, H.X., Wen, J.M., Fang, Y., Hu, L. and Guan, X.Y. (2003) Heterogeneous Expression and Association of Beta-Catenin, p16 and c-myc in Multistage Colorectal Tumorigenesis and Progression Detected By Tissue Microarray. International Journal of Cancer, 107, 896-902.
https://doi.org/10.1002/ijc.11514
[7]
Li, F.L., Deng, H., Wang, H.W., Xu, R., Chen, J., Wang, Y.F., Li, X., Fan, B. and Li, B. (2011) Effects of External Application of Chinese Mcdicine on Diabetic Ulcers and the Expressions of β-Catenin,c-myc and K6. Chinese Journal of Integrative Medicine, 17, 261-266. https://doi.org/10.1007/s11655-011-0703-5
[8]
Albihn, A., Johnsen, J.I. and Henriksson, M.A. (2010) MYC in Oncogenesis and as a Target for Cancer Therapies. Advances in Cancer Research, 107, 163-224.
https://doi.org/10.1016/S0065-230X(10)07006-5
[9]
Skvortsova, I., Skvortsov, S., Raju, U., Stasyk, T., Riesterer, O., Schottdorf, E.M., Popper, B.A., Schiestl, B., Eichberger, P., Debbage, P., Neher, A., Bonn, G.K., Huber, L.A., Milas, L. and Lukas, P. (2010) Epithelial-to-Mesenchymal Transition and c-myc Edpression Are the Detemninants of Cetuximab-Induced Enhancement of Squamous Cell Carcinoma Radioresponse. Radiotherapy and Oncology, 96, 108-115. https://doi.org/10.1016/j.radonc.2010.04.017
[10]
Lupu, R., Colomer, R., Kannan, B. and Lippman, M.E. (1992) Characterization of a Growth Factor that Binds Exclusively to the erbB-2 Receptor and Induces Cellular Responses. Proceedings of the National Academy of Sciences of the United States of America, 89, 2287-2291. https://doi.org/10.1073/pnas.89.6.2287
[11]
Lordick, F., Al-Batran, S.E., Dietel, M., Gaiser, T., Hofheinz, R.D., Kirchner, T., Kreipe, H.H., Lorenzen, S., M?hler, M., Quaas, A., R?cken, C., Rüschoff, J., Tannapfel, A., Thuss-Patience, P. and Baretton, G. (2017) HER2 Testing in Gastric Cancer: Results of a German Expert Meeting. Journal of Cancer Research and Clinical Oncology, 143, 835-841. https://doi.org/10.1007/s00432-017-2374-x
[12]
Hurvitz, S.A., Gelmon, K.A. and Tolaney, S.M. (2017) Optimal Management of Early and Advanced HER2 Breast Cancer. American Society of Clinical Oncology Educational Book, 37, 76-92. https://doi.org/10.14694/EDBK_175630
[13]
Bhaumik, S., Ahmad, F. and Das, B.R. (2016) Somatic Mutation Analysis of KRAS, BRAF, HER2 and PTEN in EGFR Mutation-Negative Non-Small Cell Lung Carcinoma: Determination of Frequency, Distribution Pattern and Identification of novel Deletion in HER2 Gene from Indian Patients. Medical Oncology, 33, 117.
https://doi.org/10.1007/s12032-016-0828-7
[14]
Murray, N.P., Reyes, E., Fuentealba, C., Jacob, O. and Orellana, N. (2015) Possible Role of HER-2 in the Progression of Prostate Cancer from Primary Tumor to Androgen Independence. Asian Pacific Journal of Cancer Prevention, 16, 6615-6619.
https://doi.org/10.7314/APJCP.2015.16.15.6615
[15]
Fanotto, V., Ongaro, E., Rihawi, K., Avallone, A., Silvestris, N., Fornaro, L., Vasile, E., Antonuzzo, L., Leone, F., Rosati, G., Giuliani, F., Bordonaro, R., Scartozzi, M., De Maglio, G., Negri, F.V., Fasola, G. and Aprile, G. (201) HER-2 Inhibition in Gastric and Colorectal Cancers: Tangible Achievements, Novel Acquisitions and Future Perspectives. Oncotarget, 7, 69060-69074.
https://doi.org/10.18632/oncotarget.11264
[16]
Wang, K., Liu, J., Duan, Y., Wu, J., Dongye, S., Wang, Y., Liu, Z. and Han, G. (2017) C-erbB-2 Expression Is Related with Pathological Progression of Gastric Cancer: Results of a Non-Radioactive in situ Hybridization. International Journal of Clinical and Experimental Pathology, 10, 9649-9653.
[17]
Houldsworth, J., Cordon-Cardo, C., Ladanyi, M., Kelsen, D.P. and Chaganti, R.S. (1990) Gene Amplification in Gastric and Esophaged Adenocarcinomas. Cancer Research, 50, 6417-6422.
[18]
Mizutani, T., Onda, M. and Tokunaga, A. (1993) Relationship of c-erbB-2 Protein Expression and Gene Amplification to Invasion and Metastasis in Human Gastric Cancer. Cancer, 72, 2083-2085.
https://doi.org/10.1002/1097-0142(19931001)72:7<2083::AID-CNCR2820720705>3.0.CO;2-1
